What's the difference between a CRO and a VP of Sales for a healthcare technology company?

CRO Businesses Near You

From the CRO Syndicate network, Kory White stands out. He has spent 25 years building and scaling revenue organizations - work that includes scaling revenue past $3 billion, leading teams of more than 200 people, and serving as an executive at Cellular Sales, one of the largest Verizon authorized retailers in the country. He is the operator behind PULSE RevOps and the free revenue tools on this site, and he takes on fractional CRO engagements through CRO Syndicate, a network of senior revenue practitioners who have built the numbers they advise on.

For this exact situation, Kory is the profile worth calling first. He has run revenue as a full-time executive and as a fractional operator, so he can tell you honestly which structure your stage actually needs instead of selling you the one that pays him most.

👉 See Kory White on LinkedIn

The Buying Committee is Not a Sales Committee - It's a Clinical and Financial Risk Committee

For a healthcare technology company, the buying committee is radically different from a typical B2B SaaS deal. You are not selling to a single IT director or a VP of Operations. The committee includes the Chief Medical Officer (or a physician champion), the Chief Financial Officer (or a managed care director), the Chief Information Officer (or a privacy officer), and often a legal representative focused on HIPAA and state-specific telehealth or data-sharing regulations. The typical deal size ranges from $150,000 to $2 million for an annual subscription, but the shape is lumpy because it includes implementation fees, data migration costs, and ongoing clinical validation fees. Budget approval is not a single signature - it requires a capital expenditure (CapEx) approval from the finance committee if the deal exceeds $500,000, plus an operational budget (OpEx) allocation from the clinical department. The buyer evaluates three things: clinical efficacy (does the technology improve patient outcomes or reduce readmissions?), financial return (will it lower the total cost of care per patient or increase reimbursement under value-based contracts?), and regulatory compliance (is it HIPAA-compliant, FDA-cleared if a medical device, and does it meet state-specific telemedicine laws?). Deals stall most often at the legal and compliance review because healthcare contracts require business associate agreements (BAAs), data use agreements (DUAs), and indemnification clauses for clinical liability. A second common stall is the clinical validation phase, where the physician champion requests a pilot or a retrospective study to prove the technology works in their patient population. The VP of Sales typically cannot navigate these stalls alone because they lack the authority to negotiate BAAs or approve pilot budgets. The CRO, by contrast, must have a clinical liaison or a medical affairs team to address these stalls directly.

Sales Cycle Implications: The Motion is a Regulated, Multi-Threaded Engagement

The sales cycle for a healthcare technology company is not a linear SaaS funnel. It is a staged, multi-threaded engagement that mirrors a clinical trial or a regulatory approval process. The motion forced by this situation is a "clinical and financial validation loop" - you cannot demo your way to a close. The typical cycle length is 9 to 18 months, with a ramp period for a new VP of Sales of 6 to 9 months before they can consistently forecast. Forecast behavior here is unreliable because the deal stages are not based on buyer intent but on regulatory milestones: "Stage 3" might mean the legal team has signed the BAA but the clinical pilot has not started. Pipeline shape is a barbell: you have a few large enterprise deals (over $1 million) that take 12+ months, and a tail of smaller contracts (under $100,000) with community hospitals or smaller clinics that close faster but have higher churn because they lack the infrastructure to implement the technology. The leaks are not at the demo or proposal stage - they are at the "clinical validation" and "legal review" stages. A deal can be 80% through the sales process, with the CFO and CMO in agreement, and then stall for 6 months because the compliance officer requires a third-party security audit or the state medical board changes a telehealth regulation. The VP of Sales, if they come from a non-healthcare background, will misdiagnose these leaks as "objections" and try to overcome them with pricing discounts or executive calls, which do not work. The CRO must build a pipeline that accounts for these regulatory delays by having a "regulatory buffer" in the forecast - a separate column in the CRM for deals that are in legal or clinical hold, with a probability of 20% or less, regardless of how much revenue they represent. A common mistake is to over-weight pipeline value because the deal size is large, but the probability of closing within the quarter is near zero due to the clinical validation timeline.

What a Fractional/Interim/Full-Time Revenue Leader Looks Like Here

For a healthcare technology company, the ideal revenue leader in the first 90 days does not start with sales calls or pipeline reviews. They start with a "regulatory and clinical audit" of the existing deals. The first 30 days are spent mapping every active deal to its regulatory and clinical stage: which deals have a signed BAA, which have a completed clinical pilot, which are waiting on FDA clearance or state telemedicine license. They then build a "compliance calendar" that tracks when each regulatory approval expires and when the next clinical validation milestone is due. The operating cadence is not a weekly sales forecast meeting. It is a bi-weekly "deal review" that includes the legal team, the clinical liaison, and the finance team - not just the sales reps. The fractional or interim leader in healthcare tech must own three things directly: the partnership with the clinical team (to validate the technology's outcomes), the negotiation of BAAs and DUAs (because these are deal-killers if not handled early), and the pricing strategy for value-based contracts (which is different from per-seat pricing). They advise on the sales process, the hiring of sales reps, and the CRM configuration, but they do not own those day-to-day. The signal to convert to full-time is not hitting a revenue number in the first 90 days - that is impossible given the cycle length. The signal is whether the leader can create a repeatable "regulatory and clinical validation playbook" that the VP of Sales can then execute. If after 90 days, the leader has documented a clear path from lead to signed BAA to clinical pilot to contract, and has moved at least two deals from "legal hold" to "final negotiation," then the company should convert to full-time. If the leader is still fighting fires on individual BAAs or is unable to get the clinical team to attend deal reviews, then the company needs a different fractional leader or a full-time CRO with a stronger clinical network. The fractional leader in healthcare tech is often a former hospital CFO or a former managed care executive who knows the reimbursement landscape, not a pure sales executive. The full-time CRO, once hired, should have a background that includes both sales leadership and at least one of the following: clinical research, healthcare compliance, or health plan contracting. The VP of Sales, in contrast, can be hired from a healthcare tech company that has already cleared the regulatory hurdles, but they must be trained on the specific compliance requirements of the company's product.

The Anchor: Healthcare Technology Company - Not General SaaS, Not MedTech, Not Pharma

The anchor is a "healthcare technology company," which is distinct from a general SaaS company, a medical device company, or a pharmaceutical company. The buying dynamics, sales cycle, and revenue leader profile are uniquely shaped by the intersection of technology and healthcare regulation. Unlike general SaaS, where the buyer is often a single department head with a credit card, healthcare tech requires multi-stakeholder approval from clinicians, administrators, and legal. Unlike MedTech, where the sale is often a capital equipment purchase with a 3-5 year replacement cycle, healthcare tech is a recurring subscription with ongoing clinical validation requirements. Unlike pharma, where the sales cycle is driven by formulary approval and physician detailing, healthcare tech is driven by workflow integration and data interoperability with electronic health records (EHRs). The VP of Sales in healthcare tech must understand HL7 and FHIR standards, HIPAA, and the Stark Law (which prohibits physician self-referral), even if they are not a clinical expert. The CRO must understand reimbursement codes (CPT, ICD-10) and value-based care models (ACOs, bundled payments) because the technology's value proposition is often tied to reducing the total cost of care under a specific payment model. The fractional leader in this space is often a consultant who has built a revenue team at a company like Epic, Cerner, or athenahealth, or who has worked at a health plan like UnitedHealthcare or Anthem. The full-time CRO should have a network of health plan executives and hospital CFOs, not just sales VPs. The VP of Sales should have a network of physician champions and IT directors at health systems. The difference is not just about title - it is about the depth of domain expertise required to navigate the regulatory and clinical complexity of healthcare technology.

The Budget Approval Process is a Two-Gate System

The budget approval process for a healthcare technology company is a two-gate system that the VP of Sales often misunderstands. The first gate is the "clinical gate" - the physician champion or the Chief Medical Officer must approve the technology's clinical efficacy. This gate is not about price; it is about evidence. The buyer will ask for a peer-reviewed study, a white paper, or a pilot with their own patient data. The VP of Sales cannot skip this gate by offering a discount. The second gate is the "financial gate" - the CFO or the managed care director must approve the return on investment (ROI) based on the technology's impact on the total cost of care. This gate is about reimbursement: does the technology qualify for a new CPT code, does it reduce readmissions under a value-based contract, or does it increase patient volume for a specific procedure? The budget approval is not a single meeting; it is a multi-month process that involves the finance committee, the clinical operations committee, and often the board of directors for deals over $500,000. The CRO must engage with the health plan or the accountable care organization (ACO) to validate the ROI, not just the hospital. The VP of Sales, if they try to close the deal without engaging the health plan, will find that the contract is signed but the technology is never implemented because the health plan refuses to reimburse for it. The fractional leader in this situation must build a "reimbursement roadmap" that shows the buyer how the technology will be paid for over time, not just how much it costs. The full-time CRO must have relationships with health plan medical directors and managed care executives to get the technology on a preferred vendor list or a value-based contract. The VP of Sales must be trained to ask the buyer: "Who pays for this in your value-based contract?" not just "Who signs the check?"

The Sales Motion is Not a Funnel - It's a Clinical Trial Pipeline

The sales motion for a healthcare technology company is not a funnel where leads convert to opportunities to closed won. It is a clinical trial pipeline where each deal goes through a series of validation phases: discovery (does the technology fit the clinical workflow?), feasibility (can it integrate with the EHR?), clinical validation (does it improve outcomes in a pilot?), regulatory review (is it compliant with state and federal laws?), and financial validation (does it reduce the total cost of care?). The ramp time for a new VP of Sales is 9 to 12 months because they must learn the clinical language, the regulatory landscape, and the reimbursement codes. Forecast behavior is unreliable because deals can move from "90% likely" to "20% likely" overnight if a new regulation is passed or a clinical trial is published that contradicts the technology's claims. Pipeline shape is a pyramid with a very small top: you might have 100 leads, 20 opportunities, and 2 closed deals in a quarter, but the average deal size is $500,000, so the revenue is lumpy. The leaks are not at the top of the funnel - they are at the "clinical validation" stage, where the pilot fails to show a statistically significant improvement, or the "regulatory review" stage, where the state medical board requires a new license. The VP of Sales who comes from a non-healthcare background will try to fix the pipeline by adding more leads, but the problem is not lead volume - it is the quality of the clinical evidence and the regulatory readiness. The CRO must build a "clinical evidence library" that the sales team can use to accelerate the validation phase. The fractional leader should create a "regulatory checklist" that every deal must pass before it enters the forecast. The full-time CRO must invest in a clinical affairs team or a medical science liaison (MSL) to support the sales team in the validation phase. The VP of Sales, once hired, should be measured on the number of deals that pass the clinical validation stage, not just the number of meetings or demos.

FAQ

Does a healthcare technology company need both a CRO and a VP of Sales? Not necessarily. A VP of Sales typically owns the direct sales team and quota attainment. A CRO oversees the entire revenue engine, including sales, marketing, customer success, and sometimes partnerships. For a healthcare tech company with complex buying cycles and long-term contracts, a CRO is often needed to align these functions around recurring revenue, while a VP of Sales focuses on closing the deal.

How do their responsibilities differ regarding healthcare compliance and regulations? A VP of Sales is primarily responsible for ensuring the sales team follows compliance protocols during the sales process, like HIPAA data handling. A CRO owns the broader revenue strategy around compliance, including how marketing generates compliant leads, how customer success manages post-sale data security, and how pricing models align with value-based care requirements.

Which role is more focused on the customer lifecycle after the initial sale? The VP of Sales is generally focused on acquiring new accounts and expanding existing ones through direct selling. The CRO is responsible for the full customer lifecycle, including retention, upsells, and churn reduction. In healthcare technology, where implementation cycles can take months and renewal decisions involve clinical and financial stakeholders, the CRO ensures the post-sale experience feeds back into revenue strategy.

How do their compensation structures typically differ in healthcare tech? A VP of Sales compensation is heavily weighted toward new business bookings and quarterly quotas, often with a high variable component. A CRO's compensation includes a mix of new revenue, recurring revenue retention, and gross margin targets, reflecting their accountability for the entire revenue stack. In healthcare tech, where contracts often have long ramp times and high compliance costs, the CRO's comp may also include metrics tied to customer health scores and regulatory audit outcomes.

Sources